Sixty million people in sub-Saharan Africa live at risk of African sleeping sickness, a disease caused by parasites transmitted through the tsetse fly. In the late stage of the disease, when the parasite crosses the blood-brain barrier, the results are oftentimes fatal.
BYU chemistry professor Ken Christensen, students and collaborators at Clemson University have developed an innovative technique using biosensors to monitor the glucose level of Trypanasoma brucei parasites, which could in turn help develop treatments for the sleeping sickness.
“The unique thing about the T. brucei parasite is that it relies on host glucose for survival,” said Christensen, whose study was recently published in top-ranked journal PLOS Neglected Tropical Diseases. “We know that if you could deprive the parasites in the blood stream of glucose, the parasite will die.”
For the study, Christensen tested glucose levels to monitor the metabolism of the parasites using a genetically-encoded glucose biosensor. The biosensor combines three proteins: a cyan florescent protein, a glucose-binding protein, and a yellow florescent protein.
When the glucose-binding protein interacts with glucose in the parasite, the two fluorescent proteins move closer together. Christensen then uses the spectroscopic changes to monitor the fluorescence-intensity ratio between the yellow and cyan proteins. When the proteins are far apart, the blue light from the cyan fluorescent protein remains. But as the proteins move closer together, the blue light goes down and the yellow light from the yellow fluorescent protein increases.
This ratio is proportional to the glucose level in the parasite.
The results obtained from the biosensor provide new insights into the process through which parasites acquire and transport glucose for survival and provide a means to identify molecules that disrupt glucose levels in the parasite.
“In the long run, we hope that some of the glucose-disrupting molecules we are now identifying can be developed into therapeutics to treat African sleeping sickness,” Christensen said.
Learn more: Stopping a tiny — and deadly — fly in its tracks
The Latest on: Sleeping sickness
via Google News
The Latest on: Sleeping sickness
- New therapeutic approach to combat African sleeping sickness on February 21, 2019 at 3:59 am
Trypanosomes, which cause African sleeping sickness, under the microscope (left) and the crystal structure of the tryparedoxin dimer (right): The two inhibitor molecules are highlighted in red. […]
- Novel Approach to Treat African Sleeping Sickness on February 20, 2019 at 9:52 pm
A promising strategy to develop a suitable agent to combat African sleeping sickness has been undertaken by researchers at JGU. According to the study, a specific inhibitory agent harbors on to and de... […]
- Scientists join forces to identify a new approach to fight African sleeping sickness on February 20, 2019 at 9:01 am
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmi... […]
- Should We Kill Off Disease-Causing Pests? Not So Fast on February 20, 2019 at 7:23 am
Sleeping sickness (or trypanosomiasis), endemic to sub-Saharan Africa, is a horribly debilitating disease. When the parasitic protozoan that causes it gets into the nervous system and brain, weeks or ... […]
- Oddchester: Sweaty palms? Bloodshot eyes? Itchy feet? Google it on February 19, 2019 at 3:00 am
Which is a statistic I found while Googling “I had trouble waking up this morning. I must have been bitten by a tsetse fly and contracted African sleeping sickness. Right, Google?” I am not, by nature ... […]
- Dr. Paul Englund, Johns Hopkins scientist and teacher, dies on February 15, 2019 at 11:57 am
Dr. Paul Theodore Englund, a Johns Hopkins teacher and scientist who studied African sleeping sickness, died of Parkinson’s disease Jan. 12 at his Roland Park home. He was 80. Born in Worcester, Mass. ... […]
- Sanofi's sleeping sickness drug, fexinidazole receives marketing approval from Democratic Republic of Congo on January 31, 2019 at 8:55 pm
Sanofi announced that the marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT), more commonly known as sleeping sickness, has b... […]
- Fexinidazole, the first all-oral treatment for sleeping sickness, approved in DRC on January 30, 2019 at 6:58 am
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT), more commonly known as sleeping sickness, has been granted in the Democra... […]
- Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo on January 30, 2019 at 6:48 am
Fexinidazole will contribute to international efforts to eliminate sleeping sickness, a fatal neglected tropical disease endemic to Africa, by 2020 It is the first all-oral treatment for sleeping sick... […]
via Bing News